High expression levels of membrane-bound complement regulatory proteins such as CD46 in tumors has been shown to suppress anti-tumor T-cell responses, and may inhibit anti-tumor therapeutic activity of monoclonal antibodies, including rituximab in B-cell NHL [47]. Here, CD46 is linked to B-cell non-Hodgkin lymphoma.